Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA guidance

This article was originally published in The Tan Sheet

Executive Summary

Current regs regarding acceptance of foreign clinical studies in support of applications for marketing approval of human drugs remain unchanged despite October revisions to the Declaration of Helsinki undertaken by the World Medical Association, FDA states in a guidance for industry published in March 13 Federal Register. Agency is "reviewing its regulations to determine if it should revise [them] to incorporate new or modified standards or requirements" contained in the declaration, guidance says

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS092303

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel